HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Tuesday, 24 May 2016

NICE recommends cabazitaxel for prostate cancer

From the NICE website:

“NICE has issued final guidance recommending cabazitaxel (marketed as Jevtana by Sanofi) for some prostate cancer patients. This is a change from the appraisal committee’s draft guidance.

The committee previously did not recommend cabazitaxel because of concerns about its cost-effectiveness compared with standard treatments (such as abiraterone, enzalutamide or radium-223 dichloride).

After the medicine was turned down, Sanofi increased the discount and confirmed that it can supply cabazitaxel in intravenous bags instead of vials, reducing waste. Therefore, they have concluded that cabazitaxel is a cost-effective treatment option.

Between 2013 and 2015, over 550 patients1 accessed cabazitaxel (as a second-line treatment after docetaxel chemotherapy) through the Cancer Drugs Fund (CDF). Now, with this positive recommendation from NICE, cabazitaxel will move out of the CDF and into routine use.”

The Evidence Review Group for this appraisal was ScHARR-TAG, with the team being Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Sanderson, Duncan Chambers and Mark Clowes.  Their report is available as part of the Committee Papers here.